Patients with localized prostate cancer who have high STAT1 expression have longer cancer-specific survival times, whereas patients with advanced prostate cancer who have low STAT1 expression experience early biochemical recurrence [33]. This evidence concerns the gene STAT1 and prostate carcinoma.